S&P MD&A 2017-Revised Year In Comparison Table -1- Ref. POL. 028/2018 February 23, 2018 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock
material decrease in sales from China. The Company has plans to expand further to other potential countries and is in the process of conducting market feasibility studies in those markets. Table 1: Sales
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
shutdown. Additionally, the company incurred opportunity loss due to loss in production and sale. The production and sale volume recorded during the Quarter is summarized in below table: 1st Quarter 2019
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
Thai Financial Reporting Standard 15 (TFRS 15) regarding revenue from contracts with customers for the first time which is effective since 1 January 2019. Table 1 : Sales Revenue by Product Line for the
. Table 1 : Sales Revenue by Product Line for the Three Months period ended 30 June (3M YoY) Sales by geography Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30
effective since 1 January 2019. Table 1 : Sales Revenue by Product Line for the Three Months period ended 30 September (3M YoY) Sales by geography Consolidated financial statements Change Increase/(Decrease
division represented 7.3% and other income represented 38.6%. (See more details from Section (1) and Section (2)) Table 1: Shared comparison of revenues between year 2019 and 2018 Year Treatment of